Peter LeWitt

Summary

Affiliation: Henry Ford Hospital
Country: USA

Publications

  1. ncbi Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
    Peter A LeWitt
    Departments of Neurology, Henry Ford Hospital, Detroit, MI, USA
    Neurology 79:163-9. 2012
  2. ncbi Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, West Bloomfield, MI 48322, USA
    Clin Neuropharmacol 35:103-10. 2012
  3. ncbi CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease
    Peter LeWitt
    Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Brain Res 1408:88-97. 2011
  4. ncbi Recent advances in CSF biomarkers for Parkinson's disease
    Peter LeWitt
    Department of Neurology, Henry Ford Hospital, Michigan 48322, USA
    Parkinsonism Relat Disord 18:S49-51. 2012
  5. ncbi Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
  6. ncbi Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
  7. ncbi Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004

Collaborators

Detail Information

Publications7

  1. ncbi Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
    Peter A LeWitt
    Departments of Neurology, Henry Ford Hospital, Detroit, MI, USA
    Neurology 79:163-9. 2012
    ..The primary study objective was to assess suppression of LID by fipamezole at day 28, as measured by the levodopa-induced dyskinesia scale (LIDS), a modification of the abnormal involuntary movement scale...
  2. ncbi Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, West Bloomfield, MI 48322, USA
    Clin Neuropharmacol 35:103-10. 2012
    ....
  3. ncbi CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease
    Peter LeWitt
    Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Brain Res 1408:88-97. 2011
    ..These observations add to other neurochemical evidence that links purine metabolism to Parkinson's disease...
  4. ncbi Recent advances in CSF biomarkers for Parkinson's disease
    Peter LeWitt
    Department of Neurology, Henry Ford Hospital, Michigan 48322, USA
    Parkinsonism Relat Disord 18:S49-51. 2012
    ..The ultimate goal is for CSF biomarkers also found in peripheral biospecimens, aiding in diagnostic screening applications and providing further clues as to the etiology of PD...
  5. ncbi Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  6. ncbi Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
    ..We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment...
  7. ncbi Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004
    ..Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy...